REGN Average Annual Return 10 Years
Growth of $10,000.00
Without Dividends Reinvested Into REGN


Also see:
REGN stock yearly return 2014
REGN stock yearly return 2015
REGN stock yearly return 2016
REGN stock yearly return 2017
REGN stock yearly return 2018
REGN stock yearly return 2019
REGN stock yearly return 2020
REGN stock yearly return 2021
REGN stock yearly return 2022
REGN stock yearly return 2023
REGN YTD return
Compare REGN average annual return versus benchmarks:

S&P Average Annual Return
Dow Average Annual Return
Nasdaq 100 Average Annual Return
Russell 2000 Average Annual Return
Gold Average Annual Return
10 Year Treasury Average Annual Return
Start date: 06/17/2014
End date: 06/14/2024
Start price/share: $302.62
End price/share: $1,036.52
Dividends collected/share: $0.00
Total return: 242.52%
REGN Average Annual Return: 13.10%
Starting investment: $10,000.00
Ending investment: $34,247.28
Years: 10.00


REGN average annual return is presented with the assumption of reinvestments of any dividends on ex-date.
Regeneron Pharmaceuticals is a biotechnology company. Co.'s products include: EYLEA, which is designed for the treatment of neovascular age-related macular degeneration, diabetic macular edema, macular edema, myopic choroidal neovascularization, diabetic retinopathy, neovascular glaucoma and retinopathy of prematurity; Dupixent, which is designed for the treatment of atopic dermatitis, asthma, rhinosinusitis with nasal polyposis, eosinophilic esophagitis (in adults and adolescents) and prurigo nodularis; and Libtayo, which is designed for the treatment of metastatic or locally advanced first-line non-small cell lung cancer and metastatic or recurrent second-line cervical cancer. The REGN average annual return 10 years is shown above.

The Average Annual Return on the REGN average annual return 10 years page and across the coverage universe of our site, is a measure of the annualized return over the past ten years (or specified start date) for a given investment (up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window to capture long-term trends.

Thus, researching Average Annual Returns is good practice for investors — whether REGN average annual return 10 years or other benchmarks/peers — and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors by performing the REGN average annual return calculation with any dividends reinvested as applicable (on ex-dates).
Quotes delayed 20 minutes

Email EnvelopeFree REGN Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Don't Forget Dividends in Average Annual Return!


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Regeneron Pharmaceuticals (REGN) is categorized under the Healthcare sector; to help you further research average annual return performance across stocks, below are some other companies in the same sector:

RENB Average Annual Return
REPL Average Annual Return
RGEN Average Annual Return
RGLS Average Annual Return
RGNX Average Annual Return
RIGL Average Annual Return
RLAY Average Annual Return
RLMD Average Annual Return
RLYB Average Annual Return
RMD Average Annual Return
More Healthcare companies »

★★★★★ Based on a ranking of our entire coverage universe by highest ten year average annual return, Regeneron Pharmaceuticals (REGN) ranks in the top 25% of all stocks whose returns we have reviewed.
What has the average annual return been for REGN over the past ten years?
✔️Accepted answer: The ten year REGN average annual return has been 13.10%.

What start date was used in your REGN average annual return calculation?
✔️Accepted answer: The start date was 06/17/2014.

What end date was used in your REGN average annual return calculation?
✔️Accepted answer: The end date was 06/14/2024.

If I had invested $10,000 into REGN ten years ago, how much would I have today?
✔️Accepted answer: Today, as of 06/14/2024, you would have $34,247.28.

What does that work out to on a total return basis?
✔️Accepted answer: The REGN ten year total return ending 06/14/2024 works out to 242.52%.


Also see:
REGN stock yearly return 2014
REGN stock yearly return 2015
REGN stock yearly return 2016
REGN stock yearly return 2017
REGN stock yearly return 2018
REGN stock yearly return 2019
REGN stock yearly return 2020
REGN stock yearly return 2021
REGN stock yearly return 2022
REGN stock yearly return 2023
REGN YTD return
 

REGN Average Annual Return 10 Years | www.AverageAnnualReturn.com | Copyright © 2021 - 2024, All Rights Reserved

Nothing in AverageAnnualReturn.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.